Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBlue Cross Blue Shield NV Prior Auth Endari Covera…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NevadaPolicy N/A

    Prior authorization for sickle cell agents (Endari/L-glutamine)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Nevada policy alerts

    Know when Blue Cross Blue Shield - Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and prior authorization requirements for L-glutamine (Endari) and related sickle cell therapy requests for members served by Anthem Blue Cross and Blue Shield programs listed; intended for prescribing providers requesting PA for initiation or continuation of therapy.

    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization for sickle cell agents (Endari/L-glutamine)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed, signed prior authorization form and fax to the Prior Authorization of Benefits Center for initiation or continuation requests.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30max dose (g/day)
    2VOC events required
    5 yrs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    minimum age

    Coverage Criteria

    Initial or continuation therapy criteria

    Covered when ALL of the following are met for sickle cell indication:

    Age: Member is 5 years of age or older>=5 years
    Diagnosis of sickle cell disease (including, but not limited to, homozygous hemoglobin S, sickle hemoglobin C, sickle beta0 thalassemia, or sickle beta+ thalassemia)
    Prescriber specialty: Prescribed by, or in consultation with, a hematologist or other prescriber specialized in the treatment of sickle cell disease
    Hydroxyurea status: Member is currently receiving hydroxyurea therapy OR member has a history of intolerance or contraindication to hydroxyurea therapy
    Initiation-specific vaso-occlusive crisis (VOC) requirement: Initiation only: Member experienced two sickle cell–related vaso-occlusive crisis events within the previous 12 months while concurrently receiving hydroxyurea therapy (or member has an intolerance or contraindication to hydroxyurea)>=2 VOCs in prior 12 months
    Dose limit: Requested dose does not exceed 30 grams daily<=30 g/day

    Other labeled indications

    Additional indication-specific requirements (short bowel syndrome; mucositis/prophylaxis of chemotherapy-induced peripheral neuropathy):

    Short bowel syndrome: If diagnosed with short bowel syndrome: member is 18 years of age or older; if using recombinant human growth hormone concurrently with L‑glutamine, prescriber must indicate and, the drug should be prescribed by or in consultation with a gastroenterologist or other prescriber specialized in short bowel syndrome; if not using growth hormone, provide rationale
    Mucositis or chemotherapy‑related peripheral neuropathy: If requested for mucositis following chemotherapy or for prophylaxis of peripheral neuropathy due to oxaliplatin or high‑dose paclitaxel, the request must be prescribed by or in consultation with an oncologist
    Dose limit for other indications: Requested dose does not exceed 30 grams (6 x 5 gm packets) daily<=30 g/day

    The completed prior authorization form and any accompanying documents may contain confidential health information that is legally privileged. The information is intended only for the use of the authorized recipient and must not be disclosed to any other party except as required by law or regulation. If you are not the intended recipient, do not disclose, copy, distribute, or act on the information; instead notify the sender and arrange for return or destruction of the documents. Do not use or disclose Protected Health Information (PHI) for individuals you are not treating or who are not enrolled in your practice, including PHI transmitted by mail, fax, email, or other electronic means.

    The form must be fully completed and signed by the prescribing provider. All sections must be completed; incomplete or unsigned requests will be returned and may delay prior authorization processing.

    Coding and Dosing

    inv-04: Maximum daily dose
    Maximum daily dose30 grams per day (6 x 5 g packets)
    Dose unitsgrams per day; packets of 5 g
    ApplicabilityApplies to all labeled indications in this policy

    Provider Actions and Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for both initiation and continuation (refill) of Endari (L‑glutamine). Indicate whether the request is for initiation or continuation on the PA form and include all required clinical documentation to support the requested service.

    • Prior authorization fax numbers: 844-864-7860 (retail) or 888-209-7838 (medical injectable)
    • Specify: Initiation of therapy OR Continuation of therapy (refill)
    Documentation Required

    Hydroxyurea Requirement or Intolerance

    Document whether the member is currently receiving hydroxyurea therapy, or provide clear documentation of intolerance or contraindication to hydroxyurea. For initiation requests, if the member experienced vaso-occlusive crisis events while on hydroxyurea, include dates and supporting records; if hydroxyurea is not appropriate, include clinical rationale and relevant history.

    • Member is currently receiving hydroxyurea therapy: Yes / No

    Background

    L‑glutamine (Endari) is indicated as a disease‑modifying therapy for certain patients with sickle cell disease to reduce the incidence of vaso‑occlusive crises. The prior authorization request must document the member’s diagnosis of sickle cell disease (including genotypes such as HbSS, HbSC, sickle beta0 thalassemia, or sickle beta+ thalassemia), age, current hydroxyurea status or documented intolerance/contraindication to hydroxyurea, and a history of vaso‑occlusive crisis events when applicable.

    For initiation of Endari, the form requires that the member be 5 years of age or older and have experienced two sickle cell–related vaso‑occlusive crises within the prior 12 months while receiving hydroxyurea (unless hydroxyurea is not tolerated or contraindicated). Requests must also specify dosing that does not exceed 30 grams per day and be prescribed by, or in consultation with, a hematologist or other clinician experienced in treating sickle cell disease.

    Definitions

    inv-10: Vaso-occlusive crisis (VOC)
    Definition of VOC eventSickle cell–related painful vaso-occlusive crisis event
    Initiation frequency requirementAt least 2 VOC events within the previous 12 months
    Concurrent therapy conditionEvents must have occurred while the member was concurrently receiving hydroxyurea (or member has intolerance/contraindication to hydroxyurea)
    Documentation requiredDates of the VOC events must be provided on the PA form
    inv-11: Other L‑glutamine indications
    Short bowel syndrome contextShort bowel syndrome requests must indicate if member is using recombinant human growth hormone concurrently and be prescribed by or in consultation with a gastroenterologist or specialist
    Policy Summary
    PayerBlue Cross Blue Shield - Nevada
    PolicyPrior authorization for sickle cell agents (Endari/L-glutamine)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed, signed prior authorization form and fax to the Prior Authorization of Benefits Center for initiation or continuation requests.
    SourceLink
    On This Page
    Coverage CriteriaCoding and DosingProvider Actions and RequirementsBackgroundDefinitions
  1. If intolerance/contraindication to hydroxyurea, provide clinical documentation and rationale
  2. For initiation: document two vaso-occlusive crisis events in prior 12 months while on hydroxyurea, or documented intolerance/contraindication (include dates)
  3. Documentation Required

    Form Completion and Submission

    Complete the PA form in its entirety. The prescribing provider must complete and sign the form; include prescriber name, state license number, NPI, prescriber signature, and a return fax or phone number. Include patient identifiers and relevant dates of service. Fax completed form to the Prior Authorization of Benefits Center at 844-864-7860 (retail) or 888-209-7838 (medical injectable).

    • Required prescriber fields: name, state license number, NPI, signature, return fax number, return phone number
    • Include patient identifiers and dates of service (for retroactive PA, submit separate with dates prior to 30 calendar days)
    • Fax numbers: 844-864-7860 (retail) or 888-209-7838 (medical injectable)
    Denial Risk

    Incomplete or Unsigned Request

    Incomplete or unsigned PA requests will be returned and will delay or prevent authorization. Ensure every section of the form is filled out and the prescriber signature is present prior to submission.

    • Unsigned or incomplete forms will be returned to the provider
    • Retroactive PA requests require separate submission when dates of service are more than 30 calendar days prior to submission
    Mucositis contextIf requested for mucositis following chemotherapy, therapy must be prescribed by or in consultation with an oncologist
    Peripheral neuropathy prophylaxisUse for prophylaxis of peripheral neuropathy due to oxaliplatin or high-dose paclitaxel must be prescribed by or in consultation with an oncologist